Navigation Links
Clinical Trial Results on the Sleep-Promoting Effects of Vanda Pharmaceuticals' Circadian Regulator Tasimelteon (VEC-162) Published in The Lancet
Date:12/1/2008

t, rotating and early riser), travel across time zones, delayed sleep phase syndrome, advanced phase syndrome and the non-24-hour sleep-wake syndrome in the blind. These disorders represent a large public health problem and, as presented in the 2006 Institute of Medicine (IOM) report on sleep disorders(5), the annual economic impact of sleep problems due to night shift work alone is estimated to exceed $65 billion.

The novel circadian regulator tasimelteon holds promise for the treatment of patients with misalignments of the body clock. The work presented in The Lancet examines the potential application in sleep disorders. Additional clinical trials will have to be conducted to examine the role of circadian regulators in the treatment of other disorders such as depression, nondipper hypertension(3)(4), and others.

CAUTIONARY NOTE REGARDING FORWARD-LOOKING STATEMENTS

Various statements in this release are "forward-looking statements" under the securities laws. Words such as, but not limited to, "believe," "expect," "anticipate," "estimate," "intend," "plan," "targets," "likely," "will," "would," and "could," and similar expressions or words, identify forward-looking statements. Forward-looking statements are based upon current expectations that involve risks, changes in circumstances, assumptions and uncertainties. Vanda is at an early stage of development and may not ever have any products that generate significant revenue. Important factors that could cause actual results to differ materially from those reflected in the company's forward-looking statements include, among others: delays in the completion of Vanda's clinical trials; a failure of Vanda's product candidates to be demonstrably safe and effective; Vanda's failure to obtain regulatory approval for its products or to comply with ongoing regulatory requirements; a lack of acceptance of Vanda's product candidates in the marketplace, or a failur
'/>"/>

SOURCE Vanda Pharmaceuticals Inc.
Copyright©2008 PR Newswire.
All rights reserved

Page: 1 2 3 4

Related medicine technology :

1. TargeGen Affiliates Scheduled for Oral Presentation of Interim Clinical Trial Data at 2008 ASH Meeting in San Francisco for TG101348, a Potent, Selective, Oral JAK2 Inhibitor in Myeloproliferative Disease Patients
2. S*BIO Advances JAK2 Inhibitor SB1518 into Phase 1/2 Clinical Trial in Australia for the Treatment of Chronic Idiopathic Myelofibrosis
3. Proteolix to Present Clinical and Preclinical Data at the 50th Annual Meeting of the American Society of Hematology
4. Pharmacyclics Announces Completion of Phase 1 Clinical Trial of Factor VIIa Inhibitor PCI-27483
5. Light Sciences Oncology Completes Patient Enrollment in Phase 3 Clinical Trial of Litx as a Treatment for Hepatocellular Carcinoma
6. CVBT Doses First Patient in its Phase II Clinical Trial for Severe Coronary Heart Disease
7. Schering-Plough Provides Update on Boceprevir Clinical Development and Introduces Potent Next-Generation Oral HCV Protease Inhibitor for Treating Patients With Chronic Hepatitis C
8. PreMD Inc. Enters Clinical Study with Cosmetics Conglomerate
9. Medarex Announces Initiation of Phase 1b Clinical Development Program with MDX-1106 for the Treatment of Cancer
10. Pharmos Announces Clinical Results from Phase 2a Trial of Topical Diclofenac NanoEmulsion Cream
11. Hologic Releases the Results of the Cervista(TM) HPV Clinical Trials
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:8/29/2014)... , Aug. 29, 2014  United Therapeutics Corporation (NASDAQ: ... District Court for the District of New ... the company,s case against Sandoz, Inc. regarding United Therapeutics, ... Sheridan ruled that U.S. Patent No. 6,765,117 is ... Sandoz from marketing its generic product until the expiration ...
(Date:8/29/2014)... /PRNewswire-iReach/ -- ChemImage will present a workshop focused on ... Forensic Science Society,s 22 nd International Symposium ... Australia .  Forensic Scientists will be in ... imaging can bring to examination procedures. ... Product Development at ChemImage, will host a workshop ...
(Date:8/29/2014)... MENLO PARK, Calif. , Aug. 29, ... (OTCQB: DMPI) ("DelMar" "the Company") today announced the filing ... Company recently changed its fiscal year end to June ... its common stock on a national securities exchange in ... as filed with the United States Securities Exchange Commission ...
Breaking Medicine Technology:District Court Decision Received In Remodulin Patent Case 2ChemImage to Discuss Hyperspectral Imaging for Forensic Investigation at the ANZFSS 22nd International Symposium on the Forensic Sciences 2ChemImage to Discuss Hyperspectral Imaging for Forensic Investigation at the ANZFSS 22nd International Symposium on the Forensic Sciences 3DelMar Pharmaceuticals Fiscal 2014 Year End Results and Summary of Recent Developments 2DelMar Pharmaceuticals Fiscal 2014 Year End Results and Summary of Recent Developments 3DelMar Pharmaceuticals Fiscal 2014 Year End Results and Summary of Recent Developments 4DelMar Pharmaceuticals Fiscal 2014 Year End Results and Summary of Recent Developments 5
... England, 4th May 2007 - CeNeS Pharmaceuticals plc,(LSE: ... of an independent study in the respected scientific,journal ... 5161. CeNeS,is developing CNS 5161 as a potential ... the work that CeNeS has,already undertaken with CNS ...
... - New data from a,randomized, double-blind study ... injection) along with the oral,antibiotic minocycline reduced ... 63 percent (p=0.08) in patients with active,relapsing-remitting ... imaging (MRI), compared to those receiving,COPAXONE(R) alone. ...
Cached Medicine Technology:Independent publication supports the profile of CeNeS phase II,compound, CNS 5161 2Independent publication supports the profile of CeNeS phase II,compound, CNS 5161 3Treatment with Copaxone Plus Minocycline Showed Substantial,Reduction of Disease Activity in Patients with Active,Relapsing-Remitting Multiple Sclerosis 2Treatment with Copaxone Plus Minocycline Showed Substantial,Reduction of Disease Activity in Patients with Active,Relapsing-Remitting Multiple Sclerosis 3Treatment with Copaxone Plus Minocycline Showed Substantial,Reduction of Disease Activity in Patients with Active,Relapsing-Remitting Multiple Sclerosis 4Treatment with Copaxone Plus Minocycline Showed Substantial,Reduction of Disease Activity in Patients with Active,Relapsing-Remitting Multiple Sclerosis 5
(Date:8/30/2014)... Ticket Down is a reliable ... in NYC. This popular ticket exchange has ... day session, evening session, courtside seats, grandstand seats, general ... Grand Slam Tournament. , The 2014 U.S. Open Tennis ... Tennis Championship: Men's/Women's 3rd Round - Session 11 Tickets ...
(Date:8/30/2014)... 2014 Acne is a common problem millions of ... nothing more than a daily nuisance, for some, it can have ... acne can even lead to dramatic mood swings and depression. ... to clear up their skin. In some cases, that can make ... trial and error, those on a quest for clearer skin can ...
(Date:8/30/2014)... 2014 Hundreds of Byetta lawsuits ( ... move forward in U.S. courts, Bernstein Liebhard LLP reports. ... July 31, 2014, Byetta and Bydureon (an extended-release version ... claims that allege the drugs caused pancreatitis, pancreatic cancer ... these claims are pending in a multidistrict litigation underway ...
(Date:8/30/2014)... Randy Dotinga HealthDay Reporter ... five patients operated on for broken bones or other orthopedic ... study finds. Less-educated patients and patients who had ... be "doctor shoppers," said study lead author Dr. Brent Morris, ... said, the study suggests that doctors aren,t talking to one ...
(Date:8/30/2014)... Pittsburgh, PA (PRWEB) August 30, 2014 ... the result of a car accident," said one of ... constant muscle strain in her shoulder and neck area. ... we invented reduced pain and pressure, assisting in comfort ... for the patent-pending PILLOW CRADLE to support the head, ...
Breaking Medicine News(10 mins):Health News:US Open Tennis Tickets: Ticket Down Slashes Ticket Prices for Labor Day Weekend Sessions and More 2Health News:US Open Tennis Tickets: Ticket Down Slashes Ticket Prices for Labor Day Weekend Sessions and More 3Health News:US Open Tennis Tickets: Ticket Down Slashes Ticket Prices for Labor Day Weekend Sessions and More 4Health News:US Open Tennis Tickets: Ticket Down Slashes Ticket Prices for Labor Day Weekend Sessions and More 5Health News:Acne Treatment Reviews Added to Popular Treatment Website 2Health News:Byetta Lawsuits Move Forward, as Bernstein Liebhard LLP Notes Settlements in More than 80 Cases 2Health News:Byetta Lawsuits Move Forward, as Bernstein Liebhard LLP Notes Settlements in More than 80 Cases 3Health News:'Doctor-Shopping' for Painkillers Common After Broken-Bone Surgery, Study Finds 2Health News:'Doctor-Shopping' for Painkillers Common After Broken-Bone Surgery, Study Finds 3
... , WEDNESDAY, Aug. 17 (HealthDay News) -- ... than one-third of lower leg injuries treated in U.S. ... Alternative approaches to treatment, such as an emergency hotline ... emergency department resources, researchers from Massachusetts General Hospital in ...
... A co-worker,s rudeness can have a great impact on relationships ... published online in the Journal of Organizational Behavior . ... intense that, at the end of the day, it is ... the worker,s family and partner, who in turn takes the ...
... -- The risk of deep vein thrombosis -- a sometimes deadly ... surgery -- is low when preventive measures such as anti-clotting drugs ... cases of deep vein thrombosis, or DVT, that occur after general ... study, published in the Aug. 15 online edition of the journal ...
... back on current expenses and largely unable to meet essential ... to a new poll from The SCAN Foundation and the ... poll, in its second year, sought to better understand health ... current economic crisis and the rising number of Californians older ...
... TUESDAY, Aug. 16 (HealthDay News) -- Drinking moderate amounts ... dementia, according to a review of previous research. ... Medicine analyzed data from more than 365,000 people who ... 1977. Moderate drinkers were 23 percent less likely ...
... new study has shown the Flexible-Fiber CO2 laser to ... (TSC) without the,line of sight problems encountered with conventional ... Medical Center (BMC) and Boston University School of Medicine ... Neurosurgery . This is the first study to report ...
Cached Medicine News:Health News:Sprained Ankles Straining ER Resources, Study Finds 2Health News:Baylor University study finds consequences of co-worker rudeness are far-reaching 2Health News:Central Catheters May Raise Risk of Blood Clots After Surgery 2Health News:Poll finds two-thirds of California voters unprepared for costs of growing older 2Health News:Poll finds two-thirds of California voters unprepared for costs of growing older 3Health News:Poll finds two-thirds of California voters unprepared for costs of growing older 4Health News:Moderate Drinking May Help Prevent Alzheimer's, Other Dementia 2Health News:Moderate Drinking May Help Prevent Alzheimer's, Other Dementia 3Health News:Study finds flexible-fiber CO2 laser safe in endoscopic endonasal transsphenoidal surgery 2
... an extremely accurate digital A-scan system. The ... probe and fast precise algorithm enables scan ... along the visual axis. The A5500 A-scan ... monitor, built-in thermal printer, 5 different examination ...
... is extremely portable, weighing slightly more than ... system provides a large liquid crystal display. ... noise probe and fast precise algorithm enables ... probe along the visual axis. The Microscan ...
... Accurate, efficient and easy to use. The ... variety of regressive, theoretical, and adaptive IOL ... the patient. Convenient design features improve your ... hands-free operation, audible tone to minimize corneal ...
... Ultrasonic A-Scan offers so many ... package. Besides,its compact and lightweight ... measurement and easy operation.,Furthermore, it ... and manual gate.,NIDEK is proud ...
Medicine Products: